Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: A Hoosier Oncology Group Protocol

C. Blanke, R. Ansari, R. Mantravadi, R. Gonin, R. Tokars, W. Fisher, K. Pennington, T. O'Connor, S. Rynard, M. Miller, L. Einhorn

Research output: Contribution to journalArticle

137 Scopus citations

Abstract

Purpose: Here we report the results of a phase III study, to evaluate whether the addition of cisplatin to radiation therapy (XRT) would improve progression-free survival or overall survival for patients with locally advanced unresectable non-small-cell lung cancer (NSCLC). Patients and Methods: Two hundred forty patients with biopsy-proven unresectable NSCLC without distant metastases or lower-stage medically inoperable patients were randomized to one of two treatment arms. Arm A consisted of thoracic XRT alone, 60 to 65 Gy total tumor dose in daily fractions of 1.80 to 2.00 Gy; and arm B consisted of identical XRT with the addition of cisplatin 70 mg/m2 every 3 weeks for three cycles beginning on the first day of irradiation. Results: Two hundred fifteen patients were eligible and assessable. The overall response rate was 50% on the combination arm versus 38% on the XRT- alone arm (P = .076). The median progression-free survival time was 23 versus 22 weeks, respectively (P = .0537). The median survival time was 43 weeks on the combination arm versus 46 weeks on the XRT arm (P(overall) = .3469). The 1-, 2-, and 5-year survival rates were 43%, 18%, and 5% on the combination arm versus 45% 13%, and 2% on the XRT arm, respectively. Conclusion: Cisplatin, administered every 3 weeks, does not significantly improve response rate, progression-free survival, or overall survival when added to thoracic XRT for locally advanced unresectable NSCLC.

Original languageEnglish (US)
Pages (from-to)1425-1429
Number of pages5
JournalJournal of Clinical Oncology
Volume13
Issue number6
DOIs
StatePublished - Jun 1995

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: A Hoosier Oncology Group Protocol'. Together they form a unique fingerprint.

  • Cite this

    Blanke, C., Ansari, R., Mantravadi, R., Gonin, R., Tokars, R., Fisher, W., Pennington, K., O'Connor, T., Rynard, S., Miller, M., & Einhorn, L. (1995). Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: A Hoosier Oncology Group Protocol. Journal of Clinical Oncology, 13(6), 1425-1429. https://doi.org/10.1200/JCO.1995.13.6.1425